FOXP1 is a member of the FOX family of transcription factors whose gene is located in a region harbouring frequent mutations in breast carcinoma cells. Therefore, FOXP1 has been postulated as a potential tumour suppressor. Its expression has been considered to be regulated by sex steroids and the status of FOXP1 has been reported to be associated with better clinical outcome of ER positive patients. However, its status in ER negative patients has not been explored. In addition, to this FOXA1, an established marker of molecular apocrine breast cancer in tandem with FOXP1 were suggested to form an regulatory loop with androgens in prostate carcinoma hence it has become important to evaluate the potential correlation of FOXP1 expression with FOXA1, AR and androgen synthesising enzymes in triple negative breast cancer patients considering the importance of androgen actions in these tumours. We first immunolocalized FOXP1 in a series of 105 triple negative breast cancers from Ramathibodi Hospital Thailand. The status of FOXA1, AR and the androgen metabolizing enzymes, 5αR1 and 17βHSD5 has already been reported in this cohort. In this cohort nuclear FOXP1 expression was present in 44% (47/58) samples. In this analysis FOXP1 status was not associated with FOXA1, AR or 17βHSD expression but significantly with 5αR1 positivity (p=0.03) and tended to be associated with AR/5αR1/17βHSD triple positive cases (p=0.06). Further analysis of publically available microarray series of triple negative breast cancers revealed that FOXA1 expression was specific to the LAR subtype but FOXP1 was elevated in all AR expressing samples. These findings all suggest a potential role of FOXP1 in the co-ordination of androgen intracrinology with androgen action in triple negative breast cancer patients.